FDA Immunotherapy Approvals: First Half of 2026
FDA immunotherapy approvals in the first half of 2026 demonstrate the continued evolution of cancer immunotherapy beyond conventional checkpoint inhibition, with major advances in cellular therapies…
Read the full articleYou might also wanna read
Cancer therapies in 2026: a new era of hope
Cancer therapies in 2026: a new era of hope newspress_en Tue, 07/07/2026 - 11:15 Infographics A 2024 report by the International Agency for
FDA-awarded RMAT designations continue to surge in 2025, reveals GlobalData
Since the FDA first awarded a regenerative medicine advanced therapeutic (RMAT) designation in 2017, activity in this space remained relativ
Realizing the potential of agonistic antibody immunotherapy
Agonistic antibodies show promise in immune therapy but have limited patient success. Recent advances could change this. Retweet if interest
<![CDATA[Pembrolizumab Plus EV Regimens Receive FDA Approval for Muscle Invasive Bladder Cancer]]>
<![CDATA[FDA OKs Pembrolizumab/EV Combo in Muscle Invasive Bladder Cancer]]>
Antibody-Drug Conjugates in Perioperative Treatment of Muscle-Invasive Bladder Cancer: Expert Perspectives
Are your treatment plans for MIBC current? Learn about the latest guidelines for perioperative antibody-drug conjugate (ADC)-based combinati
mdsc.pe·10d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.